Osteoporosis: drug market to decline, despite demand surge
This article was originally published in Scrip
Executive Summary
Despite higher patient numbers and drug volumes, the anti-osteoporotic drug market is set to decline in value over the next 10 years, concludes of a new analysis to be published shortly by Datamonitor Healthcare (Market and Product Forecast: Osteoporosis).